Abbott Laboratories Stock Filter Stocks by Fundamentals
| ABT Stock | USD 118.13 0.37 0.31% |
Abbott Laboratories fundamentals help investors to digest information that contributes to Abbott Laboratories' financial success or failures. It also enables traders to predict the movement of Abbott Stock. The fundamental analysis module provides a way to measure Abbott Laboratories' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Abbott Laboratories stock.
Abbott | Shares Owned by Institutions |
Abbott Laboratories Current Valuation Drivers
We derive many important indicators used in calculating different scores of Abbott Laboratories from analyzing Abbott Laboratories' financial statements. These drivers represent accounts that assess Abbott Laboratories' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Abbott Laboratories' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 99.5B | 127.0B | 249.8B | 190.9B | 171.8B | 180.4B | |
| Enterprise Value | 118.0B | 142.7B | 259.0B | 199.8B | 179.9B | 188.9B |
Abbott Laboratories ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Abbott Laboratories' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Abbott Laboratories' managers, analysts, and investors.Environmental | Governance | Social |
Abbott Laboratories Institutional Holders
Institutional Holdings refers to the ownership stake in Abbott Laboratories that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Abbott Laboratories' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Abbott Laboratories' value.| Shares | Wells Fargo & Co | 2024-06-30 | 16.8 M | Jpmorgan Chase & Co | 2024-06-30 | 14.8 M | Legal & General Group Plc | 2024-06-30 | 14.3 M | Bank Of New York Mellon Corp | 2024-06-30 | 14.2 M | Polen Capital | 2024-09-30 | 13.9 M | State Farm Mutual Automobile Ins Co | 2024-09-30 | 13.6 M | Massachusetts Financial Services Company | 2024-09-30 | 13.3 M | Charles Schwab Investment Management Inc | 2024-09-30 | 12.6 M | Fisher Asset Management, Llc | 2024-09-30 | 11.1 M | Vanguard Group Inc | 2024-09-30 | 167.9 M | Blackrock Inc | 2024-06-30 | 131.1 M |
Abbott Fundamentals
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0649 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.19 % | ||||
| Current Valuation | 212.08 B | ||||
| Shares Outstanding | 1.73 B | ||||
| Shares Owned By Insiders | 0.53 % | ||||
| Shares Owned By Institutions | 77.65 % | ||||
| Number Of Shares Shorted | 14.07 M | ||||
| Price To Earning | 24.14 X | ||||
| Price To Book | 5.13 X | ||||
| Price To Sales | 4.97 X | ||||
| Revenue | 40.11 B | ||||
| Gross Profit | 24.58 B | ||||
| EBITDA | 10.61 B | ||||
| Net Income | 5.72 B | ||||
| Cash And Equivalents | 9.88 B | ||||
| Cash Per Share | 5.68 X | ||||
| Total Debt | 15.87 B | ||||
| Debt To Equity | 0.46 % | ||||
| Current Ratio | 1.86 X | ||||
| Book Value Per Share | 22.94 X | ||||
| Cash Flow From Operations | 7.26 B | ||||
| Short Ratio | 2.83 X | ||||
| Earnings Per Share | 3.29 X | ||||
| Price To Earnings To Growth | 2.29 X | ||||
| Target Price | 129.87 | ||||
| Number Of Employees | 114 K | ||||
| Beta | 0.72 | ||||
| Market Capitalization | 204.89 B | ||||
| Total Asset | 73.21 B | ||||
| Retained Earnings | 37.55 B | ||||
| Working Capital | 8.83 B | ||||
| Current Asset | 14.15 B | ||||
| Current Liabilities | 9.19 B | ||||
| Annual Yield | 0.02 % | ||||
| Five Year Return | 1.54 % | ||||
| Net Asset | 73.21 B | ||||
| Last Dividend Paid | 2.2 |
About Abbott Laboratories Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Abbott Laboratories's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Abbott Laboratories using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Abbott Laboratories based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Abbott Stock Analysis
When running Abbott Laboratories' price analysis, check to measure Abbott Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abbott Laboratories is operating at the current time. Most of Abbott Laboratories' value examination focuses on studying past and present price action to predict the probability of Abbott Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abbott Laboratories' price. Additionally, you may evaluate how the addition of Abbott Laboratories to your portfolios can decrease your overall portfolio volatility.